Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?

To: Strong Long who wrote (1786)	3/28/2016 3:11:31 PM
From: Strong Long	Respond to of 2026

And forgot to mention, profitability target of 2017

To: Strong Long who wrote (1786)	3/28/2016 3:59:54 PM
From: mokelumne river	Respond to of 2026

Thanks for your summary SL. I just listened to the replay. Pascoe confirmed what I suspected, than moving forward with Fis would have required tens of millions of dollars. So that is off the table and I am relieved of that aspect and the uncertainty of the outcome of Phase III trials. The company placed a bet on Fis and lost the bet. At least tens of millions were not lost on that bet. Yes, we are back to Vitaros, a topical drug that many of us have followed for years. Unlike many micro-biotechs, the company has a product that is approved and being marketed in Europe with increasing sales, that is providing revenue, and that stands a reasonable chance of being approved in the US within a year. The picture could be a lot worse.